Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Antagonism of the prostaglandin D2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation.

In English

Författare

Summary, in English

Background: Mast cell-derived prostaglandin D-2 (PGD(2)), may contribute to eosinophilic inflammation and mucus production in allergic asthma. Chemoattractant receptor homologous molecule expressed on TH2 cells (CRTH2), a high affinity receptor for prostaglandin D-2, mediates trafficking of TH2-cells, mast cells, and eosinophils to inflammatory sites, and has recently attracted interest as target for treatment of allergic airway diseases. The present study involving mice explores the specificity of CRTH2 antagonism of TM30089, which is structurally closely related to the dual TP/CRTH2 antagonist ramatroban, and compares the ability of ramatroban and TM30089 to inhibit asthma-like pathology. Methods: Affinity for and antagonistic potency of TM30089 on many mouse receptors including thromboxane A(2) receptor mTP, CRTH2 receptor, and selected anaphylatoxin and chemokines receptors were determined in recombinant expression systems in vitro. In vivo effects of TM30089 and ramatroban on tissue eosinophilia and mucus cell histopathology were examined in a mouse asthma model. Results: TM30089, displayed high selectivity for and antagonistic potency on mouse CRTH2 but lacked affinity to TP and many other receptors including the related anaphylatoxin C3a and C5a receptors, selected chemokine receptors and the cyclooxygenase isoforms 1 and 2 which are all recognized players in allergic diseases. Furthermore, TM30089 and ramatroban, the latter used as a reference herein, similarly inhibited asthma pathology in vivo by reducing peribronchial eosinophilia and mucus cell hyperplasia. Conclusion: This is the first report to demonstrate anti-allergic efficacy in vivo of a highly selective small molecule CRTH2 antagonist. Our data suggest that CRTH2 antagonism alone is effective in mouse allergic airway inflammation even to the extent that this mechanism can explain the efficacy of ramatroban.

Publiceringsår

2007

Språk

Engelska

Publikation/Tidskrift/Serie

Respiratory Research

Volym

8:16

Dokumenttyp

Artikel i tidskrift

Förlag

BioMed Central (BMC)

Ämne

  • Respiratory Medicine and Allergy

Nyckelord

  • Disease Models
  • Cultured
  • Asthma: immunology
  • Bronchoalveolar Lavage Fluid: cytology
  • Bronchial Hyperreactivity: physiopathology
  • Bronchial Hyperreactivity: immunology
  • Asthma: pathology
  • Enzyme-Linked Immunosorbent Assay
  • Animal
  • Cells
  • Carbazoles: pharmacology
  • Female
  • Prostaglandin Antagonists: pharmacology
  • Inbred BALB C
  • Mice
  • Inflammation: pathology
  • Inflammation: drug therapy
  • Pulmonary Eosinophilia: immunology
  • Immunization
  • Animals
  • Pulmonary Eosinophilia: pathology
  • Radioligand Assay
  • Receptors
  • Immunologic: antagonists & inhibitors
  • Prostaglandin: antagonists & inhibitors
  • Sensitivity and Specificity
  • Sulfonamides: pharmacology
  • Asthma: drug therapy

Status

Published

Forskningsgrupp

  • Lung Biology
  • Respiratory Immunopharmacology

ISBN/ISSN/Övrigt

  • ISSN: 1465-9921